Femtobiomed Inc.
Femtobiomed develops CellShot, a microfluidic non-viral electroporation gene-delivery platform for cell and gene therapy.
As of 2026-10-10, Femtobiomed Inc. has 2 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded 2011, listed on KONEX in 2019, Femtobiomed develops a non-viral gene delivery platform for cell and gene therapy. Core products: the CellShot system (BADGER series, MENORAH-7000) using microfluidic electroporation, plus CellShot Cartridges, Proliva Buffer, and Cryoliva solution. It completed FDA DMF registration for CellShot Badger in August 2024, supplying pharma and CDMO clients.
Products & technology
- CellShot System (BADGER series, MENORAH-7000)Device delivering mRNA, DNA, and other genetic material into cells via microfluidic continuous-flow electroporation
- CellShot CartridgeConsumable microfluidic chip cartridge used with the CellShot system
- Proliva Buffer / Cryoliva Freezing SolutionDedicated buffer for the electroporation process and a low-DMSO cell cryopreservation solution
- SmartDropAnalytical instrument measuring fluid surface tension, solid contact angle, and solid surface energy
R&D and key agreements
Source: DART corporate disclosureCellShot® Badger FDA DMF 등록 · 등록완료 · Completed DMF (Drug Master File) registration with the U.S. FDA for the CellShot Badger device in August 2024
Key disclosures
KRX KIND via OpenDARTPublications
PubMed · affiliation-matched- Nanoinjection system for precise direct delivery of biomolecules into single cells.
Lab on a chip · 2019-02 · Yun CK, Hwang JW, Kwak TJ 외 5
- Fabrication of In Vitro Cancer Microtissue Array on Fibroblast-Layered Nanofibrous Membrane by Inkjet Printing.
International journal of molecular sciences · 2017-11 · Park TM, Kang D, Jang I 외 6
Patents
KIPRIS · applicant-matchedPublished · 2025-12 · Application 1020250203497
Published · 2025-12 · Application 1020250189697
Published · 2025-12 · Application 1020250188497
Published · 2025-09 · Application 1020250123720
EP · Published · 2023-09 · Application 23875173.9
PCT · Published · 2023-09 · Application PCT/KR2023/015094
US · Published · 2023-02 · Application 18107466
Registered · 2022-10 · Application 1020220128485
US · Published · 2019-11 · Application 16677540
Withdrawn · 2019-11 · Application 1020190141960
Show 23 more patents
CN · Published · 2019-11 · Application 201980067605.3
EP · Published · 2019-11 · Application 19883676.9
PCT · Published · 2019-11 · Application PCT/KR2019/014988
Withdrawn · 2019-10 · Application 1020190123276
US · Published · 2018-10 · Application 16151935
US · Registered · 2018-04 · Application 15962626
PCT · Published · 2018-04 · Application PCT/KR2018/004808
JP · Registered · 2018-04 · Application 30566952
Expired · 2018-04 · Application 1020180048007
US · Registered · 2015-12 · Application 14980682
JP · Registered · 2015-12 · Application 29535710
JP · Registered · 2015-12 · Application 29535711
EP · Registered · 2015-12 · Application 15202528.4
Registered · 2015-12 · Application 1020150178183
Registered · 2015-12 · Application 1020150178130
Rejected · 2015-12 · Application 1020150178234
US · Registered · 2015-05 · Application 15314438
EP · Registered · 2015-05 · Application 15798839.5
Registered · 2014-05 · Application 1020140064405
EP · Registered · 2014-02 · Application 14882044.2
Withdrawn · 2014-02 · Application 1020167026292
Registered · 2013-10 · Application 1020130129633
Registered · 2013-07 · Application 1020130090559
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive1
- OpenAIOAI-SearchBot3
- AnthropicClaudeBot2
- PerplexityPerplexityBot2
- MicrosoftBingbot1
- GoogleGoogleOther1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 1, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Femtobiomed Inc. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.
Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition